Tilray Rises Following Trump's Video Highlighting CBD's Medical Advantages for Seniors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 29 2025
0mins
Tilray Stock Surge: Tilray (TLRY) shares rose 17.5% in premarket trading following a video posted by former President Donald Trump promoting the medical benefits of hemp-derived CBD for seniors.
Medicare Coverage Proposal: Trump suggested that including CBD under Medicare could be a significant health initiative for seniors, potentially saving the healthcare system $64 billion annually if cannabis is fully integrated.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRON
Wall Street analysts forecast CRON stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.730
Low
2.30
Averages
2.72
High
3.14
Current: 2.730
Low
2.30
Averages
2.72
High
3.14
About CRON
Cronos Group Inc. is a global cannabinoid company engaged in building disruptive intellectual property by advancing cannabis research, technology and product development. The Company’s diverse international brand portfolio includes Spinach, PEACE NATURALS and Lord Jones. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, edibles and tinctures. Lord Jones is a premium adult-use cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer and edible categories. Lord Jones Ice Water Hash Fusions pre-rolls feature flower and terpene-rich ice water hash and are fitted with a branded ceramic tip. PEACE NATURALS is a global medical brand engaged in producing cannabis products. The Company distributes products under the PEACE NATURALS brand for the Canadian market and the Israeli, German, and United Kingdom medical markets.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- International Market Strength: Cronos Group achieved a record net revenue of $45.2 million in Q1 2026, reflecting a 40% year-over-year increase, with significant contributions from international markets, showcasing the company's potential for global expansion and competitiveness.
- Canadian Market Share Gains: The Spinach brand ranked #1 across all vape formats with a 9.8% market share and held an 11.1% share in vape cartridges, indicating the company's leadership position and product popularity in the Canadian market.
- Acquisition Progress: The company expects to complete the acquisition of CanAdelaar in summer 2026, which will position it prominently in Europe's adult-use cannabis market, further enhancing its international business footprint.
- Capital Return Program: Cronos announced a renewed $50 million share repurchase program, coupled with its $822 million cash reserves, demonstrating the company's flexibility in capital allocation and commitment to shareholder returns.
See More
- Significant Earnings Increase: Cronos Group reported a first-quarter profit of $13.75 million, translating to $0.04 per share, a substantial rise from last year's $6.12 million and $0.02 per share, indicating a marked improvement in the company's profitability.
- Strong Revenue Growth: The company's revenue surged by 40.1% to $45.21 million compared to $32.26 million last year, reflecting robust market demand and the effectiveness of its sales strategies.
- Market Performance Recovery: With both revenue and earnings growth, Cronos Group demonstrates stronger resilience in a competitive market, potentially attracting more investor interest in its future growth prospects.
- Improved Financial Health: The ongoing revenue and profitability enhancements suggest that Cronos Group's financial health is improving, laying a solid foundation for future expansion and investment opportunities.
See More
- Significant Revenue Growth: In Q1 2026, Cronos Group achieved net revenue of $45.2 million, a 40% year-over-year increase, primarily driven by strong sales in Israel and other countries, highlighting the company's robust growth potential in international markets.
- Improved Gross Margin: The gross profit for Q1 was $19.2 million, reflecting a 39% increase from the previous year, driven by higher average sales prices and increased sales volumes, further solidifying the company's competitive position in the market.
- Leading Market Share: The Spinach® brand captured the #1 position in the Canadian vape market for the first time with a 9.8% market share, while maintaining its top position in edibles, showcasing the strength of its brand portfolio and innovation capabilities.
- Strong Financial Position: As of Q1 2026, Cronos Group reported cash and cash equivalents of $822 million, demonstrating the company's financial strength and flexibility for future investments and expansions.
See More
- Earnings Announcement: Cronos Group is set to release its Q1 2023 earnings on May 11 before market open, with consensus EPS estimated at $0.01 and revenue projected at $42.29 million, reflecting a robust 31.1% year-over-year growth that will provide critical insights into the company's financial health.
- Positive Market Reaction: Cannabis stocks are experiencing a surge following the DEA's rescheduling move, and as a key player in the industry, Cronos may benefit from heightened market sentiment, potentially driving its stock price upward.
- International Expansion Strategy: Cronos is actively pursuing its European expansion and aims to stabilize margins through the acquisition of CanAdelaar, a strategy that will enhance its competitiveness in international markets and support sustainable growth.
- Strong Financial Position: Despite market fluctuations, Cronos Group maintains a strong balance sheet, indicating its relative undervaluation in the industry, which is likely to attract increased investor interest moving forward.
See More
- Growing Market Demand: Spinach STIX®, Cronos' latest cylindrical pre-roll, is designed to meet surging consumer interest in this popular format, with the pre-roll category accounting for over 33% of retail sales in the Canadian cannabis market, indicating strong market potential.
- Impressive Sales Figures: In March 2026, cylindrical pre-rolls generated over $17 million in Canadian retail sales, reflecting consumer preferences for portable, even-burning, and smooth smoking experiences, which further drives growth in this category.
- Product Expansion Strategy: Spinach STIX® is now available in multiple provinces including Alberta, British Columbia, and Manitoba, aiming to meet evolving consumer preferences by offering a sleeker pre-roll option, thereby enhancing the brand's competitive position in the market.
- Strengthening Brand Positioning: Cronos is focused on optimizing its high-quality product lineup, positioning Spinach® as one of the most reliable cannabis brands in Canada, thereby solidifying its leadership in the rapidly growing market.
See More
- Meeting Schedule: Cronos Group will hold its 2026 Annual Meeting of Shareholders on June 18, 2026, at 11:00 a.m. ET in a virtual format, ensuring equal participation for all registered shareholders and proxyholders.
- Participation Details: The meeting will be conducted via live audio webcast, allowing shareholders to ask questions and vote online, which enhances shareholder engagement and interaction, thereby improving corporate governance transparency.
- Replay Availability: A replay of the meeting will be accessible approximately 24 hours after its conclusion in the investor relations section of the company's website, ensuring that shareholders who could not attend live can still access the meeting content.
- Company Overview: Cronos is an innovative global cannabis company focused on scaling leading consumer goods products through R&D and innovation, aiming to build an iconic brand portfolio to elevate the consumer experience.
See More








